| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.8 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | 0.025 | 0.8 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.0082 | 0.9 |
| mRNA | PD-0332991 | FIMM | pan-cancer | AAC | -0.03 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.008 | 0.9 |